DRUG PRESCRIBING IN HEPATOBILIARY DISEASE

被引:19
作者
ROBERTS, RK
DESMOND, PV
SCHENKER, S
机构
[1] VET ADM HOSP,DEPT MED,NASHVILLE,TN 37203
[2] VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37203
关键词
D O I
10.2165/00003495-197917030-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Liver disease in man is associated with a variety of pathophysiological processes which may influence the disposition of drugs in several ways. Interpretation of the observed pharmacokinetic changes in liver disease requires an understanding of the relationship between systemic drug clearance (Cls), volume of distribution (Vd)and the elimination half-life [t1/2(β)], i.e. t1/2(β) = 0.693· Vd/Cls.Half-life will be a measure of the fluctuation in drug level one may expect with continued administration of a drug while clearance will determine the dose required to achieve a particular steady state level. Liver disease may affect clearance and volume of distribution and so produce changes in half-life; in addition, alterations in plasma binding of drugs may occur and so influence free (unbound) drug levels. It is also possible that the end organ response, particularly in the case of sedative drugs, may be affected by liver disease. Other factors such as age, nutrition, smoking, and concomitant drug therapy may also influence drug elimination in patients with liver disease. At the present time, caution should be exercised in prescribing drugs to patients with liver disease and the dose should be titrated to the clinical response. The development of liver function’ tests using model or marker drugs may offer some help to the prescriber in the future and enable a less empirical approach. © 1979, ADIS Press Australasia Pty Ltd. All rights reserved.
引用
收藏
页码:198 / 212
页数:15
相关论文
共 74 条
  • [1] ALVIN J, 1975, J PHARMACOL EXP THER, V192, P224
  • [2] ANDREASEN PB, 1974, EUR J CLIN INVEST, V4, P129
  • [3] EFFECT OF CIRRHOSIS ON DISPOSITION AND ELIMINATION OF CLINDAMYCIN
    AVANT, GR
    SCHENKER, S
    ALFORD, RH
    [J]. AMERICAN JOURNAL OF DIGESTIVE DISEASES, 1975, 20 (03): : 223 - 230
  • [4] AZZOLINI F, 1972, INT J CLIN PHARM, V6, P1059
  • [5] ABSORPTIVE FUNCTION OF SMALL INTESTINE IN LIVER CIRRHOSIS
    BARAONA, E
    ORREGOM, H
    SALINAS, A
    AMENABAR, E
    TAG, F
    MALDONADO, E
    FERNANDEZ, O
    [J]. AMERICAN JOURNAL OF DIGESTIVE DISEASES, 1962, 7 (04): : 318 - +
  • [6] BIRCHER J, 1976, CLIN PHARMACOL THER, V20, P484
  • [7] BLACK M, 1975, GASTROENTEROLOGY, V69, P289
  • [8] PROTEIN-BINDING AND KINETICS OF DRUGS IN LIVER-DISEASES
    BLASCHKE, TF
    [J]. CLINICAL PHARMACOKINETICS, 1977, 2 (01) : 32 - 44
  • [9] BRANCH RA, 1973, DRUG METAB DISPOS, V1, P687
  • [10] STUDY OF FACTORS INFLUENCING DRUG DISPOSITION IN CHRONIC LIVER-DISEASE, USING MODEL DRUG (+)-PROPRANOLOL
    BRANCH, RA
    JAMES, J
    READ, AE
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1976, 3 (02) : 243 - 249